Zura Bio Limited (ZURA) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped ZURA stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotechnology company developing multi-target cytokine inhibitors for severe autoimmune diseases. At a market cap under $400M and a current share price of $4.04, ZURA trades at a severe discount relative to sell-side Wall Street models, where all seven covering analysts rate the company a Strong Buy with a median price target of $20.00. The thesis centers on its dual-target asset Tibulizumab (IL-17A / BAFF) and ZUR-121 (IL-7Rα), which target large, underserved autoimmune indications such as systemic sclerosis and alopecia areata. While pre-revenue status, ongoing quarterly losses, and impending equity dilution represent structural tail risks common to micro-cap biotech, the asymmetric upside generated by positive Phase 2 clinical catalysts supports a high-conviction bullish profile over a 1- to 5-year investment horizon. The saved 1-year distribution is P10 $2.45, P50 $6.8, and P90 $16.2.
Last analyzed · Model: gemini-3.8-flash
Zura Bio Limited Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $2.45 | Pessimistic plausible scenario |
| P50 | $6.8 | Median scenario |
| P90 | $16.2 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Unanimous Wall Street consensus with 7 Strong Buy ratings and a median price target of $20.00 reflects significant clinical undervaluation. However, binary clinical-stage biotech risks and ongoing cash burn maintain meaningful downside risk if trial readouts delay or disappoint.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this ZURA analysis generated?
October 31, 2026.
Is this a guaranteed ZURA prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full ZURA stock analysis · ZURA sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.